Press

atai Life Sciences Secures Term Loan Facility for up to $175 Million from Hercules Capital

Aug 15 • 3 min read

atai Life Sciences N.V. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the company has entered into a term loan facility for up to $175 million with Hercules Capital, Inc. (NYSE: HTGC). “The non-dilutive capital from this term loan facility combined with the cash already…

Irwin Naturals Emergence Adds New England Clinic to Its National Footprint

Aug 15 • 4 min read

Irwin Naturals Inc. (CSE: IWIN | OTC: IWINF | FRA: 97X), completed the acquisition of its first Vermont clinic, continuing what has been the rapid expansion of this nationally known brand name into the emerging field of psychedelic mental healthcare. Irwin Naturals Emergence previously acquired five ketamine clinics in Florida, one in Iowa., one in New Hampshire, and two…

Small Pharma Receives Approval for DMT-Assisted Psychotherapy and SSRI Drug Interaction Study

Aug 15 • 3 min read

Small Pharma Inc. (TSXV: DMT | OTCQB: DMTTF), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it has received approval from the U.K. Medicines and Healthcare products Regulatory Authority and the Regional Ethics Committee to initiate a drug interaction clinical trial in the U.K. The study will assess…

Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments

Aug 15 • 2 min read

Awakn Life Sciences Corp. (NEO: AWKN | OTCQB: AWKNF | FSE: 954), a biotechnology company, researching, developing, and delivering psychedelic therapeutics to treat addiction, announced today that Awakn Clinics London has received Care Quality Commission’s (CQC) formal approval to begin treatments for addiction and mental health. The flagship London clinic is Awakn’s third clinic, adding…

Core One Labs’ Subsidiaries Successfully Produce Psilocin Precursor for Production to Psilocybin

Aug 15 • 3 min read

Core One Labs Inc. (CSE: COOL | OTCQB: CLABF | Frankfurt: LD6 | WKN:A3CSSU), is pleased to announce that scientists at its wholly-owned subsidiary Awakened Biosciences Inc. have successfully produced a precursor that can be efficiently converted into psilocin, the psychoactive ingredient of psilocybin, with further conversion into commercially viable psilocybin by Core One’s wholly owned…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441